24-Nov-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Wednesday, December 3, 2025 at 1:20 p.m. ET. An audio webcast of the fireside chat can be acc
30-Oct-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its third-quarter 2025 financial results and affirmed its key clinical development milestones. We have several important catalysts on the horizon during the next 12 months for our key programs, said Carmine Stengone,
28-Aug-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at September Investor Conferences Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September. Cantor Global Healthcare Conference 2025 fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET. Morgan Stanley 23rd
5-Aug-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical development milestones. Key Clinical Development Milestones The Company expects to report topline data from its ongoing PIPE-307 Phase 2 VISTA rela
15-May-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section
14-May-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones. We remain on track to achieve all of our clinical operations milestones and significant clinical data readouts, said Carm
12-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineums websit
6-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones. 2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the
3-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section o
24-Nov-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Miami on Wednesday, December 3, 2025 at 1:20 p.m. ET. An audio webcast of the fireside chat can be acc
30-Oct-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its third-quarter 2025 financial results and affirmed its key clinical development milestones. We have several important catalysts on the horizon during the next 12 months for our key programs, said Carmine Stengone,
28-Aug-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at September Investor Conferences Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the following investor conferences in September. Cantor Global Healthcare Conference 2025 fireside chat on Thursday, September 4, 2025, at 9:10 a.m. ET. Morgan Stanley 23rd
5-Aug-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its second-quarter 2025 financial results and updated its key clinical development milestones. Key Clinical Development Milestones The Company expects to report topline data from its ongoing PIPE-307 Phase 2 VISTA rela
15-May-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 RBC Capital Markets Global Healthcare Conference on Tuesday, May 20th at 8:30 a.m. ET. An audio webcast of the presentation can be accessed on the Investors section
14-May-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its first-quarter 2025 financial results and affirmed its key clinical development milestones. We remain on track to achieve all of our clinical operations milestones and significant clinical data readouts, said Carm
12-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the Stifel 2025 Virtual CNS Forum on Tuesday, March 18th at 12:30 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section of Contineums websit
6-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today reported its fourth-quarter 2024 financial results and affirmed its key clinical development milestones. 2025 is shaping up to be a pivotal year, as we have several important clinical data readouts and trial initiations on the
3-Mar-2025 3:05 PM CST - Business Wire Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 3:00 p.m. ET. An audio webcast of the presentation can be accessed on the Investors section o
